NCT02799095: A trial that was reported late by Mural Oncology, Inc
This trial has reported, although it was 359 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02799095 |
|---|---|
| Title | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1 |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 14, 2016 |
| Completion date | March 27, 2023 |
| Required reporting date | March 26, 2024, midnight |
| Actual reporting date | March 21, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | 359 |